Yazar "Karabörk, Şeyda" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Does cerebrospinal fluid IL-17F distinguish normal pressure hydrocephalus from dementia?
    (2024) Karabörk, Şeyda; Çelik, Hümeyra; Turkoglu, Sule Aydin
    Aim: The neurological disorder known as normal pressure hydrocephalus (NPH), which has an unknown cause, may be treatable, and is defined by a clinical triad of symptoms. A phenomenon known as dementia refers to a decline in cognitive performance that goes beyond what may be anticipated from the typical effects of biological aging. The symptomatic similarity between these two diseases causes problems in diagnosis. The objective of our study was to compare the concentrations of IL-17A, IL-17F, IL-34, and CXCL13 in the cerebrospinal fluid (CSF) of patients with NPH and dementia for an informative laboratory diagnosis. Methods: The study included NPH and dementia cases (n=7, n=5, respectively) taken from the patients’s CSF sample by lumbar puncture (LP). The levels of IL-17A, IL-17F, IL-34, and CXCL13 were measured in the CSF of patients' with NPH and dementia by enzyme-linked assay (ELISA) and compared between the two different groups. Results: There was no difference in age between the NPH and dementia groups (p=0.5). There was no statistically significant difference was found in IL-17A (p=0.7), IL-34 (p=0.9), and CXCL13 (p=0.2) in the inflammatory marker analysis in the CSF. The groups had a statistically significant difference in IL-17F (p=0.04). Conclusion: IL-17F can be an important laboratory marker used in the differential diagnosis of NPH and dementia.
  • [ X ]
    Öğe
    Protective Effects of Aronia melanocarpa Extract against Cyclophosphamide-Induced Delayed Toxicity on the Bladder
    (2025) Çelik, Hümeyra; Karabörk, Şeyda; Saylan, Aslihan; Çetınkaya, Ayhan
    Aim: Aronia melanocarpa is a red-purple medicinal fruit known for its therapeutic properties in the urinary system by anti-inflammatory effects with high antioxidant content. The aim of the study is to show the supportive effect of Aronia melanocarpa extract delayed toxicity on the bladder induced by cyclophosphamide (CYC) that an antineoplastic agent. Material and Methods: In the study three groups were constituted control (n=7), CYC(urotoxicity group, n=7) and CYC+ARONIA(treatment group, n=7). 100 mg/kg CYC intraperitoneally were given to CYC and CYC+ARONIA groups and waited for 4 weeks to be created delayed toxicity. At the end of the 4 weeks, 200 mg/kg Aronia melanocarpa was administered 15 times by oral gavage every other different day to CYC+ARONIA group (1 month in total). Sacrification was performed and after serum and urine samples were taken, the bladder was released from the sphincter region with curved-tipped forceps. Bladder tissues were investigated histologically. P38 mitogen activated preotein kinase (P38 MAPK), total antioxidant (TAS) and oxidant (TOS) status were evaluated in serum and urine samples. Results: In histology, histological damage in the bladder continued in the CYC group, while Aronia melanocarpa treatment caused healing in the bladder tissue in the CYC+ARONIA group. No difference was found between the groups in terms of P38 MAPK, TAS and TOS in serum and urine samples. Conclusion: According to the experimental results, the fact that Aronia melanocarpa extract improves the histological damage caused by CYC in the delayed period, and the serum and urine findings were the same as the controls, brought up the therapeutic effect of Aronia melanocarpa in urotoxicity.